LSI Europe Summit Presenting Companies | Emerging Medtech Startups

Juan Abascal

CEO & Founder, ABANZA

ABANZA specializes in the Sports Medicine and Soft Tissue Repair market and has developed a patented platform of medical devices for soft tissue fixation, with technology designed to perform independently of bone quality and delivering market-leading biomechanical performance. The company currently has three commercial products in the U.S. and Europe, is approved across leading healthcare systems and institutions, and is expanding its platform into more than 50 surgical applications across the knee, shoulder, elbow, hand and wrist, hip, and foot and ankle. I am also attaching the company logo and my photo.

Rotem Kopel, PhD

CEO & Co-Founder, ABILITY Neurotech

ABILITY Neurotech develops a minimally invasive brain-computer interface system based on subdural ECoG electrode arrays that rest on the cortical surface rather than penetrating brain tissue. The batteryless implant transmits neural data through the skin via an optical link to an external wearable, where AI decoders translate speech- and movement-related activity into communication and device control. The company is clinical-stage, with chronic implantation studies in ALS patients underway.

Patrick Pestalozzi

CEO, Abionic

Abionic is a Swiss diagnostics company developing rapid point-of-care technologies designed to accelerate the detection of life-threatening conditions such as sepsis. The company's PSP assay has received 510(k) clearance from the FDA. At the core of the platform is abioSCOPE®, an award-winning desktop diagnostic system leveraging proprietary nanofluidic technology to deliver quantitative results within minutes from just 50 µL of blood. The platform is designed for use in emergency and acute care settings, enabling faster clinical decision-making and earlier intervention for critically ill patients.

Christopher Carlton

Chairman and CEO, Accure Acne

Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment.

Joel Krupa

Chief Academic Officer, Agents of Discovery

Agents of Discovery empowers health and life sciences organizations, cities, universities, airports, sports teams, and other innovation hubs to create place-based learning experiences guided by interactive, AI-powered avatars. Using the Agents platform, teams can support education, workforce training, and community engagement while transforming indoor and outdoor spaces into dynamic, interactive adventures.

Lucas Decuypere

CEO, Allegro

Our lead product is Hydrocelin, a first-in-class, minimally invasive injectable therapy, designed as a disease-modifying treatment for osteoarthritis. Hydrocelin is designed to address the primary cause of osteoarthritis: the loss of the rheopectic and viscoelastic characteristics of the synovial fluid. Once injected, Hydrocelin mixes with the synovial fluid, where it adapts under load to absorb and dissipate impact forces and replicate the mechanics of healthy joint fluid through resilient nanostructured crosslinking. This restores joint function and relieves pain, while initiating a mechanobiological cascade that protects and potentially regenerates cartilage. Hydrocelin does not suppress symptoms. It corrects the physics of the joint and changes the trajectory of the disease.

Sean Morris

President & CEO, Amplifi Vascular

Amplifi Vascular is developing the Amplifi™ Vein Dilation System, a proprietary blood pump technology designed to enlarge veins and improve outcomes for patients requiring arteriovenous fistula (AVF) surgery. The system is intended to increase AVF eligibility, accelerate maturation, reduce failure rates, and extend primary patency. By addressing key challenges in dialysis access, Amplifi aims to improve treatment outcomes for patients with end-stage renal disease.

Yi-Kai Lo

CEO, ANEUVO

ANEUVO's, ExaStim®, is a portable, wireless, multi-channel, non-invasive spinal stimulation system that delivers clinician-adjusted, patient-specific, non-invasive neuromodulation in both clinical and home settings. In Europe, ExaStim is CE marked for upper-extremity motor function in adults with spinal cord injury across injury stages and subtypes; in the U.S., it is FDA 510(k) cleared to improve hand sensation and strength in adults with chronic incomplete SCI when used in conjunction with functional task practice.

Nadav Agian

CEO, Append Medical

Append Medical is a clinical-stage medical technology company developing a next-generation Left Atrial Elimination (LAE) system for stroke prevention in atrial fibrillation patients. Leveraging a proprietary vacuum-based approach that eliminates the need for a permanent implant, Append aims to address the limitations of current LAA occlusion therapies by reducing the risks of device-related thrombus (DRT) and peri-device leak (PDL), while providing a transcatheter solution compatible with a broad range of patient anatomies.

Michal Jaworek

CEO & Co-Founder, Approxima

The Approxima System is a percutaneous right ventricular reshaping technology for the treatment of tricuspid regurgitation (TR) that targets the underlying cause of the disease, right ventricular dilation. Through a straightforward implantation procedure, it reshapes the ventricle and immediately restores tricuspid valve function, it aims to prevent disease progression, and preserves the native valve, enabling versatile long-term patient management. First-in-human study is underway.

Robert Kieval

President and Chief Executive Officer, Arctx Medical, Inc.

Arctx Medical, a clinical-stage medical technology company, is developing the world's first targeted treatment for Acute Pancreatitis (AP), and is introducing a superior new approach for patient temperature management. Targeted cooling is a well-established therapy for treating acute inflammatory conditions within the body. The Arctx Cool Catheter™ (ACC) Set delivers minimally invasive, selective, and potent cooling therapy to the pancreas, intended to reduce inflammation, accelerate patient recovery, and prevent more serious complications including organ failure and death. Arctx is embarking on an IDE-approved US pivotal clinical trial for this first-ever dedicated treatment for AP. In addition, Arctx now has FDA clearance for the ACC for patient temperature management, a second and mature market for its technology in which it is beginning to commercialize.

Souvik Paul

CEO & Founder, Aurie

Aurie holds FDA Class II De Novo clearance for the world's first safely reusable catheter system: one patented reusable catheter and an easy-to-use portable washer-disinfector with pre-packaged supplies replaces 100 single-use catheters at standard-of-care pricing, halving life-threatening infection risk and cutting catheterization waste by more than 67%. Incumbents have left the $3B intermittent catheter market stagnant for three decades with limited innovation. Two large RCTs (MultICath, COMPaRE) have now validated reuse and consumer demand for reusable alternatives to single-use catheters; Aurie is the only cleared system built to capture the shift.

Hilla Benpazi

Founder & CEO, Avertto Medical LTD

Avertto Medical is developing a non-invasive monitoring platform that continuously measures bilateral carotid artery pressure waveforms in hospitalized patients. The technology combines proprietary sensors and signal-processing algorithms to track physiological changes in carotid hemodynamics and provide real-time monitoring of cerebrovascular status in clinical settings.

Roger Johnston

CEO, Axial3D

Patient-specific care has historically relied on manual, bespoke workflows that are difficult to standardize and scale. As demand grows, medical device companies need a digital infrastructure capable of processing imaging, planning, and device workflows consistently at volume. Axial3D provides an AI-powered, cloud-based, configurable platform that automates these processes, enabling medical device companies to standardize and scale patient-specific programs across products, teams, and markets. Its FDA-cleared technology and regulatory infrastructure provide a foundation for scaling patient-specific solutions across medical device portfolios and making patient-specific care routine.

Lars Kongsbak

CEO, Axithra

Axithra is developing a photonics-based diagnostic platform for measuring both unbound and total drug concentrations directly from blood in approximately 15 minutes. The platform uses Raman spectroscopy to support therapeutic drug monitoring and individualised dosing in hospitals, with future applications in outpatient care.

Andrés Vásquez Quintero

CEO/CTO & Co-Founder, Azalea Vision

Azalea Vision is developing a solution for patients with conditions and disorders that increase sensitivity to light. The company's solution actively adapts and manages within a personalized contact lens. The lens will also be capable of compensating for refractive errors of the eye, such as astigmatism and myopia.

Sonia Martinez Arca

Co-founder and CEO, Batea Oncology

Batea Oncology develops innovative therapies for glioblastoma , with the aim of improving treatment outcome and patient survival rates.

Aswin Hoffmann

EiR / Co-Founder, BEAMRION

BEAMRION is developing the world's first real-time magnetic resonance imaging (MRI)-guided proton therapy platform, combining ionizing radiation-free, high soft- tissue contrast live anatomical imaging, AI for fast online and real-time adaptive treatment workflows, and beam-agnostic therapy guidance in a fully integrated clinical system. BEAMRION is building an innovative live in-beam MRI-based "GPS" solution that unlocks real-time adaptive high-precision radiation therapy for moving tumors and expands the range of radiation treatment indications even beyond oncology. BEAMRION's in-beam MRI solution is designed to be deployable and scalable as a retrofit in existing treatment rooms or fully integrated MR-guided proton therapy system into new rooms.

Alexis Peyroles

CEO, BetaGlue Therapeutics SpA

BetaGlue Therapeutics is pioneering targeted nuclear therapies for solid tumours. YntraDose, our solution, is a combination of a biocompatible bioglue and Yttrium 90 microspheres, that is designed to transform pancreatic cancer treatment through localized, effective, and safe therapy.

Jeremy Wheeler

CEO, BIOCAPTIVA LTD

BIOCAPTIVA develops

Marcus Gerhardt

CEO & Co-Founder, Blackrock Neurotech

Blackrock Neurotech designs, manufactures, and supports the world's most validated implantable brain-computer interface (BCI) systems. Our high-fidelity neural recording and stimulation technologies power advanced neuroscience research and restore independence for people with paralysis and other neurological disorders. Since 2004, our long-tested human BCI platform -- anchored by the FDA-cleared 96-channel Utah Array (K110010) -- has demonstrated an unmatched safety profile with over 55,000 days of human implant data, including the longest continuously implanted BCI in a human at over 11 years, and has enabled more than 56 patients to regain movement and communication over sustained, multi-year use.

Julien Penders

Co-Founder & COO, Bloomlife

Bloomlife has developed a tech-enabled remote prenatal monitoring platform combining its unique medical wearable for maternal-fetal monitoring, connected devices, AI-based predictive analytics and clinical services. Bloomlife shifts maternal and prenatal care from costly hospital environments to home, improving birth outcomes for moms and babies. Bloomlife contracts with clinics and leverages existing reimbursement codes to create financially accretive programs for its partners.

Carlos Bremer

Chief Strategy Officer, brain4care

A category-defining neurotech that makes intracranial dynamics visible early, turning previously invisible physiology into actionable insight to prevent brain damage. Backed by 146 publications, 49 patents, and a network of global KOLs, brain4care is redefining the magnitude and timing of intervention by enabling a real-time, bedside, and non-invasive way to assess the risk and trend of neurological deterioration over time.

Edouard Fonck

CEO, Cairdac

Cairdac is a French medtech company developing a new generation of leadless pacemakers powered by the heart itself, designed to eliminate the fundamental limitations of current cardiac pacing systems and redefine the standard of care. ALPS™ enables a fully self-powered, leadless pacemaker combining continuous monitoring, expanded pacing capabilities, and long-term autonomy. This approach allows Cairdac to overcome the key trade-offs that have so far limited the adoption of leadless technologies. The company is preparing its clinical studies

Simone Pollano

Co-founder & Investor Relations Officer, CardYograft

CardYograft develops Cardiac Micrograft Therapy (CMT), an autologous cardiac patch prepared at the point of care: during cardiac surgery, tissue from the patient's own right atrial appendage is mechanically processed in the operating room with a CE-marked disaggregation device and applied over the left-ventricular scar, in parallel with the ongoing procedure. Because the graft is autologous and prepared intraoperatively, the therapy involves no cell expansion, no cold chain and no immunosuppression, and is being developed as a Class III device under EU MDR rather than as an ATMP. Its target population is heart failure with reduced ejection fraction and post-infarction scar, initially in patients undergoing coronary artery bypass grafting, with a mini-thoracotomy access under development to extend the therapy beyond bypass candidates.

Martin French

CEO, Carelight

Carelight enables wearable, medical-grade monitoring and assessment of health biomarkers throughout the full patient journey, from home monitoring to ICU. Our goal: better health outcomes through continuous medical grade data, earlier disease detection, and improved decision-making. Our OPM technology, incorporating multi-wavelength, 3D optical sensing with AI-adaptive illumination, yields high-quality pulsatile waveforms for robust personalised cardio-respiratory insights beyond current wearables. Carelight's first product, a wrist worn pulse oximeter, overcomes skin tone related errors in non-invasive blood oxygen measurement, addressing long standing questions of iniquity in pulse oximetry devices.

Paul Sargeant

President & Chief Executive Officer, Circular Genomics

Circular Genomics is a biotechnology company revolutionizing neurological and psychiatric precision medicine. The company provides a unique understanding of dynamic brain processes that will transform how neurological and psychiatric conditions are diagnosed and managed leveraging unique, brain-enriched circular RNA biomarkers via simple blood tests. These biomarkers serve as ideal neurological biomarkers. We are advancing tests in Alzheimer’s and Parkinson’s Disease.

Magnus Jensen

CEO & Co-Founder, ClariDX

Harmless and dangerous oral lesions often look alike, prompting precautionary biopsies. However, more than 97% of oral biopsies are negative for cancer. ClariDX is developing OralClarity, a handheld Raman spectroscopy probe with a single-use tip that analyses tissue biochemistry and provides immediate lesion-risk feedback. It removes healthy patients from the treatment pathway and accelerates care for those who need it. We enter the market through specialist oral medicine and maxillofacial surgery, scale into general dentistry, and extend the platform into gastrointestinal endoscopy.

Moises Barbera Ramos

Founder and CEO, CLARO Surgical

Claro Surgical is reinventing orthopedic surgeries with the latest in mixed reality and artificial intelligence via the only FDA-registered platform: OrthoMR.

Yana Reshetnyak

CEO, CleanMargin

CleanMargin is a clinical-stage company developing the proprietary fluorescent surgical imaging agent, MarginVue, that enables surgeons to precisely visualize and remove all cancer lesions during breast-conserving cancer surgeries to achieve clean (cancer-free) surgical margins, addressing a large unmet medical need in breast cancer and many other cancer surgeries. Our ongoing Phase II clinical trials conducted at Memorial Sloan Kettering Cancer Center together with our device partner, Stryker Corp., demonstrate that MarginVue is safe and detects all sub-types of breast cancer with 100% sensitivity

Regina Atim

Founder, Clinicians Touch ALLYVE

Clinicians Touch ALLYVE is developing a wearable maternal bracelet and corresponding application that collects patient-generated data during pregnancy. The device will empower tracking of key data that can be shared with providers to improve outcomes during pregnancy.

Gregor Strobbe

Founder CEO, Clouds of Care

Clouds of Care is a technology-enabled clinical development partner focused on advancing precision medicine for people with Central Nervous System disorders. The company specializes in applying neurophysiology, digital health technologies, and its data-driven AI-powered biomarker platform to improve the detection and interpretation of treatment effects in clinical trials.

Frank K. de Gioia

CEO, Collin Robotics

Collin Robotics is a pure-play ENT robotics and navigation company that develops RobOtol, an ENT microsurgical robot with 5-micron spatial accuracy and an installation base of 27 sites across 12 countries, and a real-time electromagnetic CNS navigation system for ENT and cranial procedures, with an installation base of 326 sites across 26 countries. The company is developing a second-generation platform to extend capability to support all high-precision cranial microsurgery procedures.

Louis De Lillers

CEO, CorWave

CorWave develops and manufactures innovative implantable blood pumps based on a breakthrough membrane technology.

Claudia Rodiera, MD, PhD, EMBA

Co-Founder & Chief Medical Officer, Cufftech

Quantitative neuromuscular monitoring is essential during anesthesia and recovery to improve patient safety and help reduce postoperative respiratory complications and associated healthcare costs. Cufftech integrates quantitative neuromuscular monitoring directly into the blood pressure cuff, offering a disruptive form factor designed to make objective monitoring simple, seamless and accessible in routine clinical practice, with the goal of improving patient safety and outcomes while reducing the clinical and economic burden associated with postoperative complications. Founder-funded to date, Cufftech is currently pre-revenue and in the final stages of CE marking certification (expected Q2 2027), and is now launching its first external investment round to support commercialization and international expansion.

Joan Grasas

CEO, Debios Diagnostics

Debios Diagnostics is an IVD spin-off of IGTP, a Barcelona-based hospital research institute. Its lead product, FIBROKIT®, is a urine-based IVD for the non-invasive assessment of renal fibrosis, a key prognostic factor in chronic kidney disease (CKD), with CE marking targeted for Q4 2027. Supported by biopsy-referenced evidence in native-kidney and transplant patients, it improves fibrosis detection by 25% when used alongside albuminuria, with applications in patient stratification and monitoring across kidney transplantation, clinical nephrology and pharmaceutical R&D.

Stéphane Corp

Co-Founder & CEO, DeepPulseNeuro

DeepPulseNeuro is developing an endovascular neural interface to record intracranial electrical activity from the brain through the cerebral venous system. Starting with drug-resistant epilepsy, the technology is designed to enable less invasive access to deep-brain electrophysiology and broaden the clinical applications and patient populations that can benefit from intracranial neural monitoring.

Ludwig Gutzweiler

CTO & Managing Director, Dermagnostix

Dermagnostix manufactures and markets a fully automated, cartridge-based molecular diagnostics platform integrating sample preparation, nucleic acid amplification, and fluorescence detection on centrifugal microfluidic disks. Current applications focus on gene-expression diagnostics in dermatology, while the platform can also support molecular assays in other clinical and research fields.

Bertrand Moal

CEO, DESKi

HeartFocus is an FDA-cleared, AI-powered cardiac ultrasound platform designed to radically expand access to echocardiography. The software provides real-time acquisition guidance and automatic quality validation, enabling clinicians with minimal ultrasound training to consistently capture diagnostic-quality transthoracic echocardiographic views. By shifting image acquisition from scarce specialists to a broader clinical workforce — including nurses, PAs, and frontline providers - HeartFocus addresses a critical bottleneck in cardiac care across emergency medicine, primary care, and resource-limited environments.HeartFocus is FDA cleared and commercially available in the United States, with early customers live and active across multiple care settings - positioning the platform for rapid scale in preventive, acute, cardiac care, and educational institutions.

Stefania Riboldi

Chief Technology Officer, Dialybrid

Dialybrid develops hybrid vascular grafts based on proprietary Silkothane®, a novel composite material joining the biocompatibility of silk fibroin and the elasticity of polyurethane. The first product in the pipeline is SAG (Silkothane® Arteriovenous Graft), a semi-degradable arteriovenous graft for use as hemodialysis vascular access, offering the short-term usability of synthetic grafts and the long-term performances of native fistulae. The product is currently being tested in a first-in-human study.

Solveig Johannessen

CEO, Dova Health Intelligence

Dova is a precision health technology company that is building the AI infrastructure for how gastrointestinal (GI) health is measured, monitored, and managed. We develop AI-powered, image-based solutions that empower clinicians and researchers with actionable insights to advance GI care, as well as provide standardized, quantitative disease intelligence across clinical research and future clinical care.

Our multimodal intelligence platform includes DovaVision UC, designed to support granular assessment of ulcerative colitis at scale, and DovaSound, designed to support rapid, standardized intestinal ultrasound image capture and assessment.

Pri Hancock

CFO, Echopoint Medical

Echopoint Medical is developing the IKOR™ coronary physiology system, an advanced optical sensor technology that measures coronary microvascular function in real time during routine cath lab procedures. By enabling accurate diagnosis of coronary flow, pressure & temperature, syndromes like ischaemia with non-obstructive coronary arteries (INOCA)—a condition that disproportionately affects women—IKOR helps physicians personalize treatment and reduce unnecessary stents and repeat procedures.

Aidan Mulloy

Founder and CEO, Eclipse Medical

Eclipse Medical developed Omega, a left atrial appendage closure device for stroke prevention in nonvalvular atrial fibrillation. More than 1,000 devices have been implanted across Europe, and the company is preparing a US IDE pivotal trial, with IDE submission targeted for Q1 2027.

Veronique Ameye

CEO, ElectraDx

ElectraDx has developed the first lab-accurate, ultra-low-cost community ad home based diagnostic platform using proprietary intelligent electronic strip technology. Our device delivers results from a simple fingerstick in under10 minutes, connects securely to healthcare systems, and supports a broad test menu covering over 70% of common lab tests. With an initial focus on cardiac markers, we are shifting diagnostics from hospitals into every home to enable earlier intervention and better health outcomes.

Maria Leiloglou

CEO, Enacuity

Enacuity is an Imperial–UCL spin-out, that delivers the world's first software-only functional imaging upgrade to existing surgical cameras, improving patient outcomes.

Nahum Ferera

Co-Founder & CEO, EyeYon Medical

Mr. Nahum Ferera is an entrepreneur and medical device executive with extensive experience leading innovative technologies from concept through development, regulatory approval, and successful commercialization. Nahum is the co-founder and CEO of EyeYon Medical, where he has led the development and global commercialization of EndoArt - the world's first and only synthetic endothelial implant. EndoArt represents a breakthrough approach to the treatment of chronic corneal edema, offering a non-cellular alternative to donor tissue transplantation and addressing a major unmet need in corneal care worldwide. Under Nahum's leadership, EyeYon has advanced EndoArt from an early-stage concept into a clinically validated and commercially available technology, with growing adoption by leading corneal surgeons and ophthalmic centers across Europe and Asia. The technology has also received FDA Breakthrough Device designation and approval to initiate a pivotal clinical study in the United States. Before founding EyeYon Medical, Nahum was involved in the development of medical devices in the fields of cardiac rhythm management and non-invasive glucose monitoring. In addition to his role at EyeYon, Nahum leads the Israeli Ophthalmology CEOs Group, which includes more than 60 members. He also serves as a mentor in the Israeli Bio-Executive Forum and the International MBA Program at Tel Aviv University, and as a panelist in the International MBA Program at the Technion - Israel Institute of Technology. Nahum holds an MBA and a

Field Medical is developing a next-generation pulsed field ablation (PFA) solution for the treatment of cardiac arrhythmia. The company is building a purpose-built system that incorporates PFA, contact force sensing, electromagnetic localization, and artificial intelligence-enabled mapping capabilities to address the limitations of first-generation PFA technologies and deliver more efficacious therapy.

João Curado

CEO, Flomics Biotech

Flomics is a biotech company developing a revolutionary liquid biopsy test that combines AI with RNA biomarkers for the early detection and management of cancer and other complex diseases. From an individual RNA profile we detect molecular signs associated with the disease and its metabolic state, making sure everybody gets the right treatment at the right time. Everything from a standard blood draw.

Dr. ir. Christoff Heunis

CEO, Flux Robotics B.V.

Flux Robotics develops a magnetic navigation platform for vascular interventions. The system uses external magnetic fields to steer guidewires and microcatheters through complex vascular anatomy, supporting more controlled and predictable navigation during procedures such as blocked artery crossing and complex stent placement.

Laura Becerra-Fajardo

CEO, FORESEE MedTech

FORESEE MedTech is a deep-tech spin-off awardee of the European Innovation Council (EIC) Transition grant (2.5 M€), that is developing an intravascular multiparametric sensing platform for remote monitoring of chronic conditions, starting with heart failure. FORESEE’s solution aims to support earlier interventions, reduce hospitalizations, empower patients and improve long-term outcomes in this cardiovascular condition. Thanks to the ability to measure multiple parameters from a single intravascular device, FORESEE will improve patient management by addressing the fact that in heart failure "one size does not fit all

Simon Mifsud

Chief Executive Officer, Garland Surgical

Garland Surgical is developing the patented TriActiv Hip: a next‑generation, triaxial hip replacement system designed to meet the needs of today's modern and diverse patient population. Engineered to deliver a wider and more natural range of motion, the implant also provides exceptional stability and ultra‑low wear compared to conventional ball‑and‑socket designs, supporting both active lifestyles and long‑term durability. Developed in close collaboration with leading orthopaedic clinicians, academic partners, and industry experts, and evolved from the MaltaHip project, TriActiv Hip aims to offer a practical, long‑lasting solution for high‑demand and high‑risk patients, including those prone to dislocation and instability.

Maurits Huigen

CEO, Gilbert

Gilbert has built an enabling drug-delivery platform for the development of next-generation inhaled drug-device combinations, with pharma and CDMO partners as the commercial pathway. Gilbert's breakthrough scalable delivery platform offers the precision and adaptability modern inhaled therapies require - and the simplicity patients demand.

Raj Shah

CEO, GuideAI Health

GuideAI Health automates the early detection of chronic vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts. The platform's first product addresses the 90% underdiagnosis/misdiagnosis rate of peripheral vascular disease in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.

Arash Dodge

CEO, Haermonics BV

Haermonics' core technology enables Continuous Postoperative Pericardial Flushing (CPPF) to help reduce clot formation, maintain tube patency, and support drainage management during early recovery after cardiac surgery. The automated system is designed for use immediately after surgical closure and aims to reduce postoperative complications. Clinical studies have shown a 40% reduction in reintervention.

Christopher Lee

Co-Founder & CEO, HapticHeart Solutions, Inc.

HapticHeart Solutions is advancing a wearable haptic feedback platform—featuring a glove and armband—that restores tactile sensation in catheter-based, minimally invasive, and robotic procedures. By converting physical and physiological signals into real-time touch and force feedback, the system aims to enhance surgical precision, shorten learning curves, and improve patient outcomes. Currently at Technology Readiness Level 6, the prototype has demonstrated clinical utility in electrophysiology and is being expanded for use in robotic surgery.

Mike Connolly

CEO, Healionics Corp.

Healionics is developing safer, more reliable means of bloodstream access to support life-saving dialysis therapy in kidney failure patients. Its FDA Breakthrough-designated STARgraft AV graft has 24-month clinical results that show outstanding resistance to both occlusion and infection — the two primary causes of failure in on-market grafts. The company also has a diverse product pipeline leveraging its core STAR biomaterial technology which can inhibit scar tissue encapsulation and infection to improve the performance of a wide range of other implantable devices and facilitate creation of entirely novel ones.

Francis White

CEO, Heart Biotech Ltd

The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body's own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing.

Shamus Husheer

CEO, Heartfelt Technologies

The Heartfelt device is an autonomous, in-home monitoring device shown in a 180-patient randomized, blinded, sham-controlled study to reduce heart failure hospitalisations by over 50%, potentially saving Medicare alone over $20Bn/yr. It achieves this by using 3D imaging to measure patients' feet and lower legs as they pass the sensor during normal daily life. No patient interaction is required, largely eliminating the adherence problems associated with conventional monitoring. Foot swelling occurs in around two-thirds of heart failure patients 10–15 days before hospitalisation, providing enough warning for a nurse alert and timely intervention (e.g. increasing diuretic therapy) to prevent hospital admission.

M. Shane Ray

CEO and CCO, Hemanext, Inc.

Hemanext is a medical technology company pioneering oxygen-controlled blood processing for red blood cells, the first innovation designed to preserve red blood cell quality throughout storage. Its Hemanext ONE® platform reduces oxidative damage during storage to preserve red blood cell quality and oxygen-delivery function, helping provide higher-quality red blood cells for patients requiring transfusion. The FDA-cleared, CE-marked technology is now in commercial stage in the United States and Europe.

Jeongwon Lee

CTO, Impact Korea Co., Ltd.

Impact Korea has developed a continuous pressure management platform that automates the conventional manual pressure bag used for arterial lines. The system maintains controlled pressure and monitors abnormal conditions to support arterial catheter patency and help prevent blood backflow. The technology is relevant to critical care, arterial monitoring, interventional cardiology, interventional radiology, neurointervention, and vascular access.

Rik Kielman

CEO, Implican

Implican has developed a compression ring system to create colorectal anastomosis, creating a bacteria free wound healing environment by using only submucosa. This prevents anastomotic leakage and avoids diverting stomas. This has already been proven successful in preclinical trials and in humans in the First In Human trial.

Peter Fischer

CEO, Inkspace Imaging

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics.

Rubén Molina

CEO & Co-Founder, INNITIUS

Innitius has developed a quantitative diagnostic platform that measures cervical tissue biomechanics combined with AI models to support clinical decision-making in obstetrics. The technology addresses key use cases including threatened preterm labor, early preterm birth risk stratification, and induction of labor, enabling more accurate and objective assessment at the point of care.

Malin Nilsson

CEO, Inossia

Inossia is developing a platform technology focused on reducing repeat fractures in patients receiving bone cement for fracture repair. The company's lead product, V-Flex, is a bone cement for vertebral augmentation that hardens at a significantly lower temperature compared to competing bone cements. The soft cement is ideal for osteoporotic bones to adjacent fracture risk without compromising on mechanical support.

Harlee Sorkin

CEO, InterShunt

InterShunt is developing a minimally invasive catheter therapy for heart failure, the leading cause of hospitalization and Medicare expense. Currently in clinical phase, the procedure dynamically offloads left atrial pressure, addressing the most debilitating symptoms in patients with limited treatment options.

Shirish Joshi

CEO & Founder, Joshi Innovations

Technologies to restore depth perception in minimal invasive surgery and endoscopy. Our technology allows use of standard monocular endoscopes to do real time 3D visualisation. This is achieved by combining physical AI with advanced sensorics. We control camera sensor and light source and lenses in real-time to extract high-quality data that can be used for accurate depth estimation. First use case targeted is Laparoscopy. The technology can also be applied for very thin flexible endoscopes used in robotic endoluminal procedures such as bronchoscopy to visualize in 3D.

Theo Ruers

Co-founder and CEO, Juvant Medical

Juvant Medical has developed a technology platform for real time tissue diagnosis based on state of the art optical technology, based on light – tissue interaction and AI aided analysis. The technology is applicable throughout the full oncology care cycle, from diagnosis to treatment monitoring, informing the clinicians in real time on tissue diagnosis during biopsy or cancer surgery. SmartScan will be the first product Juvant will bring to market, directed to real time tumor margin assessment and surgical guidance during surgery.

Yuval Shklarsh

Founder & CEO, Kudu Med

Kudu Med develops ultrasound-based wireless power transfer technology for implantable medical devices. The company's platform enables safe, non-invasive recharging of implants such as pacemakers, supporting smaller devices, higher-power therapies, and reducing the need for replacement surgeries.

Ula Rustamova

CEO & Co-Founder, Level Zero Health

Level Zero Health is building the world's first real-time access point to the next major data layer in healthcare: hormones. We are developing hormone monitoring wearables with clinical-grade accuracy, giving patients and clinicians access to biological data that has never existed before.

Dr. Tim Kaufmann

Founder and Chairman, LifeShield Medical

LifeShield Medical develops and manufactures cardiopulmonary support systems for critical care and high-risk cardiac interventions. Its ECMO system is approved and marketed in China and Hong Kong (CE-approval expected in Q3/Q4 2026). A mid-flow ECMO variant for moderate-to-severe COPD and a dedicated cannula set are pending regulatory approval in China and Europe in Q3/Q4 2026. The company's purge-free percutaneous ventricular assist device (pVAD) for high-risk PCI has successfully completed multiple initial human cases and entered its regulatory study in China. The company holds 50+ patents across R&D and manufacturing operations in Germany and China with 120+ team members.

John Schindler

Co-Founder & CEO, Liquet Medical Inc.

Liquet Medical is developing catheter-based technology for the treatment of pulmonary embolism (PE). Our Versus™ Catheter combines bilateral pulmonary artery drug delivery with continuous, real-time pulmonary artery pressure monitoring through a single venous access, enabling physicians to assess hemodynamic response during catheter-directed thrombolysis.

Scott Xiao

Co-Founder and CEO, Luminopia

Luminopia is pioneering a new class of treatments for neuro-visual disorders using virtual reality technology. The company's lead product has been FDA-cleared for pediatric amblyopia, the leading cause of vision loss in children worldwide. Since launch, the product has been prescribed to 14,000+ patients and is now being covered by major insurance plans including Anthem.

Nitzan Hirsh

Co-Founder and CEO, LuSeed Vascular

LuSeed's DOME is a minimally invasive device for treating bifurcation and sidewall brain aneurysms simply and effectively. The device utilizes a braided mesh design that makes it position-agnostic within the aneurysm. Another benefit of the DOME device is its design, which minimizes protrusion to the parent artery, thereby mitigating the need for dual anticoagulation therapy.

Gunter Trojandt

Managing Director, MDA - Medical Decision Alliance GmbH

MDA is building a best-in-class surgical reference database and translating the expertise of leading surgeons into advanced, AI-powered intra-operative decision-support solutions. Backed by €4 million in seed capital, MDA has successfully validated its business model over the past 24 months. To unlock the full potential of its approach and secure long-term market leadership, MDA is now seeking further growth capital.

Vili Kostamo

Medical doctor, CEO, Co-Founder, MedicubeX

MedicubeX has developed a self-service eHealth Station™ that non-invasively measures key health markers in 5-10 minutes. Within the next 12 months the Stations start to accurately predict individuals' 10-year risk of developing heart disease or type 2 diabetes, completely without a blood test unlike anything on the market. By replacing needle pricks with simple, non-invasive health checks, it makes long-term disease prevention painless, fast, and accessible to everyone.

Deniz Ozturk

VP, In Silico Technologies, Medividia

Medividia accelerates medical-device development, testing and regulatory evidence generation by evaluating devices under physiological and patient-specific conditions or in virtual representations of standardized bench tests. Its numerical simulations capture interactions between blood flow, device and anatomy in applications including heart valves; LVADs, ECMOs; among others. These simulations complement bench, animal and clinical studies, supporting design decisions, patient selection and in silico clinical trials.

Alex Joseph

Chief Executive Officer, Microsure

Microsure develops MUSA-3, a CE-marked robotic system for open microsurgery and supermicrosurgery. The system scales and tremor-filters the surgeon's hand movements and works with standard microsurgical instruments, enabling procedures on vessels under one millimetre, such as lymphatic reconstruction for lymphedema.

Tom Moore

President & CEO, Minze Health

Minze Health is a commercial-stage medical device and digital health company combining at-home uroflowmetry (Homeflow), automated bladder diary monitoring, and a digital therapeutic for BPH (Lutastic+) into a single connected platform, with its Minze app driving strong patient engagement through symptom tracking (IPSS, OABSS, voids, fluid intake). Backed by 27 publications and 150,000+ validated data sets, Minze replaces single-point clinical snapshots with longitudinal, real-world data across a combined ~$9.3B TAM in BPH and OAB. The company serves US and EU urology practices on an ARR model, with collaborations including Medtronic, Apogepha, and Coloplast.

Christopher Gleason

President & CEO, Moximed

Moximed is a commercial-stage medical device company offering the MISHA Knee System, an FDA-authorized Implantable Shock Absorber designed to treat medial knee osteoarthritis. The device is placed on the inner side of the knee during an outpatient procedure to absorb the impact of walking, reducing joint force by 30%. Differentiated by its joint-preserving design that does not require cutting bone, Moximed bridges the gap between conservative therapies and total knee replacement, offering active patients superior pain relief and mobility.

Rudolf Schulze Vohren

Co-Founder and CEO, Nano4Imaging

Nano4Imaging develops MRI-compatible, MRI-visible interventional devices (e.g., guidewires) and AI-powered navigation software to enable catheter-based procedures under MRI guidance. The platform uses embedded marker technology and real-time image-based tracking to support device visualization and navigation while eliminating reliance on fluoroscopy and iodinated contrast.

George Kramer

Founder & CEO, NeoCor

NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach. The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery. The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure. CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.

Ana Maiques

CEO & CoFounder, Neuroelectrics

Neuroelectrics unlocks the power of computational neuroscience to treat brain disorders—pioneering non-invasive tech for personalized neuromodulation, aiming to restore brain health & improve lives.

Jonas Steinhäuser-Meerz

CEO & Co-Founder, NGScopes

NGScopes is a pre-clinical-stage medical device company based in Germany, developing a robotic instrument platform for endoscopy. NGScopes' instruments are independently steerable through the working channel of standard endoscopes, enabling precise, single-operator control without disrupting existing clinical workflows. The lead product, a robotic electrosurgical knife for endoluminal surgery, has demonstrated feasibility in ex vivo studies and is being prepared for FDA submission.

Lloyd Diamond

CEO, Nitinotes

Nitinotes Ltd. is an early commercial-stage medical device company advancing endoluminal innovation for obesity care. Its flagship platform, EndoZip™, is the first fully automated, single-operator suturing system designed specifically for endoscopic sleeve gastroplasty (ESG). EndoZip™ is engineered to improve procedural workflow, support consistency, and enhance scalability of ESG while keeping physicians in control of technique and outcomes. The company received CE Mark approval in November 2025 and has initiated focused European commercialization, including its first commercial case in Italy. In the United States, EndoZip™ is an investigational device, currently being evaluated in the pivotal EASE clinical trial. Nitinotes is positioned at the intersection of metabolic intervention, procedural innovation, and growing global demand for minimally invasive obesity solutions.

Leonhard Riehle

Chief Medical Officer and Cofounder, Noah Labs

Noah Labs Vox eliminates the no. 1 cause of hospital admissions - congestive heart failure - 3 weeks before hospitalization by analyzing voice changes caused by fluid build-up in the lungs and vocal tract. Trained on the world's largest heart failure voice data set, the patented technology is being piloted at Mayo Clinic, UCSF and Charité Berlin.

Hamed Hanafi

CEO, NovaResp Technologies Inc

cMAP® is an AI-enabled PAP platform algorithm that predicts and prevents respiratory episodes before they occur. Its personalized approach delivers therapy at lower, more comfortable pressures — driving significantly better patient adherence.

Barry McCann

CEO & Founder, NUA Surgical Ltd

NUA Surgical is a Galway-based maternal health medtech company focused on developing the SteriCISION C-Section Retractor, a disposable, self-retaining surgical tool designed to improve access, visualization, and ergonomics during Caesarean delivery while reducing surgical complications. The company's most recent funding was €6.5 million in Series A, led by EQT Life Sciences, to support manufacturing, testing, regulatory clearance, and early commercialization of the technology.

Juan Alcantara Morales

CEO, Nuubo

Nuubo delivers patient-centric cardiac monitoring with textile-based, adhesive-free electrodes enabling comfortable 30-day wear, higher compliance, and continuous clinical-grade ECG data to improve detection and care decisions.

Olivier Taelman

CEO, Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah's lead solution is the Genio system, a patient-centered, leadless externally activated hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Thomas Weindl

CEO & Co-Founder, OLI

OLI is a medical device company developing a platform for accessible, affordable kidney care. The company is building compact, low-cost systems to unlock clinical-quality hemodialysis and hemodiafiltration therapies for kidney failure patients from virtually anywhere.

Maxwell Munford

CEO & Founder, OSSTEC

OSSTEC has developed a biomimetic 3D-printing platform for cementless fixation in orthopaedics. Its first product, ASCENT, is a cementless fixed-bearing partial knee system designed to streamline surgical workflow and expand the patients who can be treated with partial knee replacement.

Laura Yecies

CEO, Osteoboost Health

Osteoboost is the first and only FDA-cleared wearable therapy for osteopenia—clinically proven to reduce bone loss in the spine. Order online with prescription.

Jerome Marzinski

CEO, OxSonics

OxSonics is a clinical stage medtech company, spun out from Oxford University, specialized in oncology drugs delivery leveraging state-of-the-Art ultrasound technology and particles which together deliver more drugs into the tumor mass. Our flagship product SonoTran was used in a first In Man trial for treating liver metastasis in mCRC, was safe and able to generate positive early efficacy signals in terms of objective response of both on and off-target liver tumors.

Alexa Buck

Co-Founder, PACATIS

PACATIS is building a personalised care platform for neurodevelopmental and neurocognitive disorders that transforms fragmented real-world data into predictive insights. By leveraging longitudinal monitoring and advanced analytics, the platform creates an individualised digital footprint that helps anticipate care needs, optimise care pathways, and facilitate earlier intervention.

Manios Dimitrakakis

CEO, Panda Surgical

Panda Surgical, a University College London spinout, is introducing the world's first robotics and AI platform for minimally invasive neurosurgery, offering surgeons enhanced dexterity and decision-support to make these operations safer, more effective, and more widely adopted.

Bill Marks

Chief Clinical Officer, Paradromics

Paradromics is building the world's most capable and clinically viable brain-computer interface (BCI) platform. Its advanced neurotechnology captures brain activity at the highest resolution, individual neurons, enabling AI-powered treatments for motor impairment, chronic pain, addiction, depression, and other neurological conditions. The company's first clinical product, Connexus® BCI, is designed to restore speech and communication for people who are unable to speak due to debilitating motor conditions.

Marcel Both

CEO, PharmaSens AG

PharmaSens is developing a fully integrated, automated insulin delivery platform that combines an insulin pump, continuous glucose monitor (CGM), and control algorithm into a single wearable device. The system is purpose-built to overcome current adoption barriers and unlock access to the ~80% of insulin-dependent patients not using pumps today.

Kristoff Goson

CEO, Pixee Medical

Knee+ NexSight brings AR-based guidance into the OR in a way that feels simple to learn, adopt, and to use. It does not ask surgical teams to reorganize around a large robotic system. It meets them where they are, with mobile guidance that fits into existing surgical environments and OR processes while helping surgeons validate alignment and execution in real time.

Christopher von Jako

CEO, Polarean

Visit our website to learn more.

Pablo Fernández

CEO, Polimerbio

Polimerbio is an early stage Medtech company dedicated to developing next generation biodegradable medical devices combining their knowledge on biomaterials and polymers science. The company has started its journey in the field of urology by developing the first intraurethral biodegradable stent for the management of urethral stricture after urethrotomy aiming at replacing the use of current non-biodegradable catheters.

Jannis Fischer

CEO, Positrigo

NeuroLF is a compact, dedicated brain PET imaging system designed to make high-quality neuroimaging more accessible and cost-effective. By combining advanced detector technology with a streamlined design, it enables earlier detection and monitoring of neurodegenerative diseases such as Alzheimer's Disesae in a wider range of clinical settings, including neurology offices.

Wolfgang Kintzel

Co-CEO & CSO, PreciPoint

PreciPoint develops an IP-protected digital pathology platform that integrates high-performance imaging hardware with proprietary software and AI-driven workflows. The platform is designed for interventional pathology applications, including point-of-care use cases such as frozen sections (FS) and rapid on-site evaluation (ROSE), providing an end-to-end digital pathology solution.

Karl Stoklosa

CEO, Precisis

EASEE is an innovative, evidence-based neurostimulation platform that offers a fully reversible, less invasive alternative to traditional treatments, reducing risks and side effects. Its first application in epilepsy care uniquely combines two therapeutic strategies to provide a safe, effective option for patients who have not responded to conventional therapies.

Michael Behr

CEO, Prolifagen

Prolifagen is harnessing the power of microRNA to induce a proliferation of regenerative cells and help restore damaged tissues to a healthier functioning state. Their first application, called PRO302, is a patented mixture of miR302 and a hydrogel (Hyaluronic Acid) that is introduced to damaged heart tissue following a heart attack. The mixture induces a proliferation of cardiomyocytes, which can promote the regeneration of the patient's heart muscle as well as prevent the build-up of scar tissue. This can help restore the heart's pumping capacity and reduce the likelihood of progression to heart failure.

Chris Lear

Chief Strategy Officer, Prometheus Therapeutics

Prometheus Therapeutics has developed the world's first Regenerative Photobiomodulation (PBM) platform to stimulate biologic healing. This is a patent-protected technology platform, and our first mission addresses the most significant unresolved clinical issue in Brain Aneurysm Care: awful long-term occlusion rates.

Mathias Bouzereau

Senior Business Development Director, International, Pulnovo

Pulnovo Medical is a globally recognized device pioneer in the treatment for Group 1 & Group 2 pulmonary hypertension(PH) and heart failure. Our pioneer technology, PADN (Pulmonary Artery Denervation), is a first-in-class interventional therapy targeting overactive sympathetic nerves around the pulmonary arteries, supported by more than 1,000 clinical and commercial cases over the past decade. Pulnovo has obtained NMPA and EU MDR approval for Group 1 PH in 2023 and 2025 respectively, and has already commercialized the PADN products in China, EU, and Middle East. In 2025, Pulnovo received two FDA IDE approvals for PADN system clinical trials and is currently conducting multiple global clinical trials.

Carl Daintree

CEO, QV Bioelectronics

QV Bioelectronics is developing GRACE, an implantable Tumour Treating Fields (TTF) device platform for treating solid tumours, initially focusing on glioblastoma (GBM). Placed during tumour resection surgery, GRACE delivers targeted TTF from within the body to disrupt cancer cell division, with an implantable design intended to maximise patient quality of life.

Dr. Margaret Kalmeta

CEO, Rapid Nexus NWS

Core technology is a drug device combination: Bioelectricity with a medicinal substance that has proven to regenerate nerves, blood vessels, connective tissue as well as other tissues. The technology's NanoString transcriptomic profile revealed a robust activation of multiple gene expression pathways and has confirmed a profound molecular shift, with dozens of Nanostring biomarkers showing significant elevation after treatment. The technology is being deployed into the VA system Q4, 2026 as a stand-alone device (with drug) while the drug device combination will enter the Breakthrough therapy pathway late Q4, 2026.

Marcin Golebicki

CEO and Founder, ReNavie Sensing

ReNavie Sensing is the new novel technology focusing on mapping Renal Denervation and solving non responder issue.

Gurpreet Singh

CEO, Respiree

Respiree delivers a three-component platform combining a wearable FDA-cleared device, AI-powered deterioration detection software, and a care coordination enterprise-level platform. Together, these automate vitals collection, reduce alarm fatigue, and generate actionable clinical insights across inpatient and translational care settings.

Marc Zemel

CEO, Retia Medical

Retia develops healthtech AI algorithms for helping guide management of surgical and critically ill patients to improve outcomes. This is a $4 billion market. The company's technology has been clinically validated and is used in 65 hospitals.

Christos Bergeles

Founder and CEO, Revitalise

Revitalise develops a robotic microsurgical platform for ultra-precise retinal therapy delivery and for procedures beyond the reach of human dexterity. The platform is therapy-agnostic, aiming to be the delivery operating system for the next generation of retinal medicine, with a global market opportunity in the billions.

Will Mauldin

CEO, RIVANNA

RIVANNA® is a medical technology company developing clinical decision-support solutions powered by proprietary clinical datasets, AI models, and purpose-built imaging hardware. The company's platform automates complex anatomical analysis at the point of care, enabling faster, more confident clinical decisions while reducing variability and expanding access to advanced capabilities. The first applications target significant market opportunities in regional anesthesia and fracture care.

Michael Gürtler

Chief Commercial Officer, RSP Systems A/S

RSP Systems has developed the world's first non-invasive glucose measurement solution based on Raman spectroscopy and proprietary algorithms. We are developing a solution for tracking of glycemic health in people that do not have diabetes with FDA submission planned for second half of 2028. Our technology is capable of identifying multiple analytes in the skin and the application space thus goes beyond glucose.

Maria Artunduaga

Founder & CEO, Samay

Samay’s Sylvee is the first wearable to match CT performance, the gold standard, for early COPD detection, identifying small airway disease up to 5 years before spirometry can detect any changes. Validated in 450+ patients (AUC 0.93) and protected by 18 patents across 20+ countries, Samay is already generating revenue with a top European respiratory pharma, a world-leading sleep company, and a top US academic medical center, while preparing for a late 2027 launch across 1,500 clinics through Latam’s third-largest payer and investor.

Jay Kapoor

Business Development Lead, Sealantium Medical

Sealantium's sFilm-FS is a transparent, flexible, biodegradable co-polymer film combined with human fibrinogen and thrombin, used as a hemostatic and sealing patch in both open and minimally invasive/robotic surgery. Current target indications include cardiovascular, liver, neurosurgery (dura sealing), GI tract/anastomosis, and lung resections.

David Gascoigne

CEO, Segmed

The critical bottleneck of healthcare AI and drug development was access to data; Segmed spent seven years solving that problem starting with medical imaging, resulting in the leading multimodal clinical data network, with 31M+ patients, 150M+ imaging exams, and a foundation already validated by 50+ FDA customers clearances. The next decade belongs not to those who move data, but to those who generate intelligence from it, which is why Segmed is extending from data delivery to AI-driven insight delivery across imaging, clinical notes, pathology, and beyond. This transition expands our addressable opportunity from real-world imaging data for AI-development to multi-modal real-world evidence for drug development and medical AI.

Chaim Lotan

Chief Innovation Officer, Hadassah Hebrew University Medical Center & SmartValves

SmartValves is developing next-generation technology for heart valves by adding a “brain” to what is currently a passive implant. Our platform is designed to enable active EGM sensing and on-demand pacing, with the potential to meaningfully impact both patient care and the healthcare system.

Our initial focus is the TAVR market, where these capabilities may support:

Systematic, Safe next-day discharge, helping patients return to normal activity sooner while supporting hospitals in optimizing capacity.
Meaningful reduction in permanent pacemaker implantation, through proactive monitoring and mitigation of conduction disturbances associated with TAVR.
Beyond TAVR, we believe the SmartValves platform can extend to tricuspid and other structural heart therapies, significantly broadening its clinical and commercial potential.

At the same time, continuous EGM acquisition creates a unique data layer that, combined with AI-driven analytics, may enable earlier detection and prediction of clinically meaningful events, expanding SmartValves from a therapeutic device into a connected patient-management platform.

Bart Bandy

Chief Executive Officer, Solenic Medical

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants.

David Jacques

CEO, Sonata Medtech

Sonata Medtech harmonizes the PFA ablation procedures with a 3rd generation pulse generator and catheter. Large inflexible carts, disliked universally by the EP Labs, are eliminated and replaced with a permanently mountable small box with industry leading output control and flexibility. Multiple catheters can be reduced to a single catheter by Sonata that can do many types of arrhythmias without mid-procedure catheter changes.

Miguel Luengo-Oroz

CEO & Founder, Spotlab.ai

SpotLab.ai builds mobile, efficient and sovereign AI to upgrade millions of existing microscopes into intelligent tools for diagnosis and clinical research. Its technology helps clinicians detect subtle patterns in microscopy images using equipment they already have, expanding access to the best healthcare for everyone, everywhere: from blood cancers to neglected tropical diseases.

Chris Hordijk

Founder/CEO, Surgical Reality

Surgical Reality converts routine diagnostic CT scans into patient-specific, interactive 3D models. Thoracic surgeons and interventional pulmonologists use the software for pre-operative resection planning and for intra-operative guidance during lung cancer surgery and bronchoscopic interventions. The platform is CE marked under MDR (Class IIa) and FDA 510(k) cleared, and is in clinical use in hospitals in the Netherlands, Germany, Belgium, Australia, Switzerland, Norway and United Kingdom.

Sanjay Kakkar

CEO, Tensive

Tensive is a clinical-stage biomaterials medical device company developing innovative bioresorbable scaffolds for breast reconstruction and tissue marking. Its patented REGENERA and SOFTAG scaffolds are designed to allow regeneration of the body's own tissue to create natural, safe and lasting reconstruction for patients recovering from lumpectomy or during cosmetic procedures. The result is restoration that preserves the original shape and feel of the patient's breast, yet is clearly differentiated from surrounding tissues on imaging.

Martin Deterre

CEO, Theraclion

Theraclion develops Sonovein®, a robotic HIFU platform that enables varicose veins to be treated fully non-invasively from outside the body, without catheter, incision, tumescent anesthesia, or operating room infrastructure. By combining real-time ultrasound imaging, robotics, and automated treatment planning, Sonovein® precisely targets and thermally closes diseased veins, creating a new treatment category beyond conventional endovenous ablation. The company is entering a scale-up phase, with commercial acceleration in Europe and the Middle East, pending regulatory submissions in the U.S. and China, and continued technological improvements to the Sonovein® platform.

Steve Motes

CEO, Tulyp Medical

Tulyp Medical is developing a pressure-guided limb perfusion system for patients experiencing reduced or disrupted blood flow to the lower limb during cardiovascular procedures. The system combines a pressure-sensing catheter with a compact pump to monitor limb perfusion and actively regulate blood delivery, with the goal of reducing the risk of procedure-associated acute limb ischemia.

Sofia Bertling

CEO, Utilizer

Utilizer has developed the first rapid, ultra-low-cost near-patient solutions for urinary tract infection testing. Its proprietary Utilizer-ID® platform is designed to provide lab-accurate pathogen identification, and antibiotic susceptibility in a streamlined workflow, delivering actionable microbiological information at the point of care. By enabling fast and informed treatment decisions, Utilizer aims to improve patient outcomes, reduce the 60% unnecessary antibiotic use, and support antimicrobial stewardship in a growing global diagnostics market.

Zeeshan Syedain

CEO, Vascudyne Inc

Vascudyne develops off-the-shelf bioengineered vascular and heart valve devices designed to regenerate into living cardiovascular tissues through host cell integration and remodeling. The platform targets major unmet needs in coronary, congenital, and structural heart disease by providing durable long-term solutions.

Adam Gridley

CEO, Vergent Bioscience

Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

Finbar Dolan

CEO, VERSONO Medical

Versono is developing an intravascular ultrasonic platform to improve the crossing of severe occlusions in the peripheral vasculature. The device will prepare a working lumen to support endovascular therapy in patients with chronic total occlusions (CTOs) and critical limb ischemia (CLI).

Tushar Sharma, PhD

CEO & Founder, Vivifi Medical Inc

Vivifi Medical is pioneering the first non-surgical, non-urethral device for treating BPH that targets the hormonal root cause rather than simply managing symptoms. By redirecting testosterone-rich blood away from the prostate, our approach results in true regression without implants, urethral instrumentation, or compromise to sexual function.

Luca Ravagnan

CEO, WISE SpA

WISE is a medical device company developing neural electrodes for neuromonitoring, neuromodulation, and brain-machine interfaces, based on its proprietary Supersonic Technology, which embeds conductive layers within soft, ultra-thin silicone to produce stretchable, conformable electrodes that adhere closely to neural tissue. Its portfolio includes the WISE Cortical Strip (WCS®), a CE-marked, FDA-cleared, and TGA-approved electrode that conforms to the cortical surface for intraoperative neurophysiological monitoring, and the Heron® lead, a directional multicolumn lead for chronic pain treatment, delivering paddle-like spinal cord stimulation percutaneously, without a laminectomy, and currently preparing for clinical validation.

Eliane Schutte

CEO, Xeltis

Xeltis is a commercial-stage medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels to address the limitations of current treatment options for the millions of patients requiring hemodialysis vascular access or cardiovascular replacements every year. The Company’s proprietary Restorex® platform utilizes an advanced polymer implant which is transformed into the patient’s own tissue before gradually being absorbed and leaving new, living vessels in place that support long-term clinical outcomes. Its most advanced product aXessTM, an implantable blood vessel for hemodialysis vascular access, has received CE Mark approval and is now being commercially deployed across Europe. Xeltis aims to improve patient outcomes by enabling the creation of living vessels to reduce the need for repeat interventions and address significant unmet needs in vascular access. The Company’s groundbreaking technology also has high potential to be applied to other major vascular and cardiovascular diseases.

Menachem Genut

Co-Founder & Chief Scientific Officer, YOPI

YOPI has developed a proprietary wearable device, worn on the upper arm, that continuously analyzes sweat to monitor key physiological electrolytes and metabolic markers in real time. The technology enables early identification of cardiovascular risk indicators—well before clinical symptoms appear, while delivering advanced performance insights, including real-time oxygen consumption (VO₂), accurate calorie expenditure, and substrate utilization (fat, carbohydrates, and proteins), along with additional critical physiological metrics. This non-invasive platform replaces traditional offline VO₂ testing and intermittent blood-based diagnostics with continuous, real-time, and clinically relevant health monitoring—effectively bringing the metabolic lab into everyday life.

Event Resources

General Resources